Under the terms of the agreement, Abbott will have exclusive rights to distribute Luminex’s new xTAG Respiratory Viral Panel (RVP) worldwide outside the US and semi-exclusive rights in the US.
Douglas Bryant, executive vice president and COO of Luminex, said: “We believe that xTAG RVP has the potential to significantly impact the detection, treatment, and control of respiratory viruses worldwide. Abbott’s long-standing dedication to improve the quality of human health, combined with their global customer base, will make them a strong partner in bringing xTAG RVP to more physicians, public health authorities and patients around the world.”